Sign up to get updates from us
To the oncologist, human physiology is a riot of redundancies, and treating cancer is a game of whack-a-mole – target one mechanism, another pops up. Anat Cohen-Dayag, scientist and CEO of Compugen has known this for years. However, to bring her expertise into the clinical realm, she needed to transform her company from a service provider of computational target discovery, into a savvy team of scientists/clinicians poised to enter the blockbuster field of cancer immunotherapy checkpoints.
